Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption

Journal of Pharmaceutical Sciences

Volumn 92, Issue 3, 2003, Pages 621-633

  Zmuidinavicius, Donatas ^a   Didziapetris, Remigijus ^a   Japertas, Pranas ^a   Avdeef, Alex ^b   Petrauskas, Alanas ^c  

^a Pharma Algorithms Inc   (Lithuania)

^b PION INC   (United States)

^c Pharma Algorithms   (Canada)

Author keywords

Absorption prediction; Bioavailability; Classification SAR; Human intestinal absorption; Permeability prediction; Recursive partitioning

Indexed keywords

ACEFYLLINE; AZOSEMIDE; BENSERAZIDE; BRETYLIUM TOSYLATE; CEFETAMET PIVOXIL; CEFPODOXIME PROXETIL; CHLORTETRACYCLINE; CILAZAPRILAT; DEMECLOCYCLINE; DIMERCAPROL; DOXYCYCLINE; ENALAPRILAT; FAMOTIDINE; FLUDARABINE PHOSPHATE; GLYCOPYRRONIUM BROMIDE; HYDROCHLOROTHIAZIDE; HYDROFLUMETHIAZIDE; IDARUBICIN; LISINOPRIL; LODOXAMIDE; MINOCYCLINE; NETIVUDINE; OXYTETRACYCLINE; PENTAERYTHRITOL; PRALIDOXIME; PYRANTEL; REPROTEROL; TETRACYCLINE; THIAZINAMIUM; UNINDEXED DRUG;

ACTIVE TRANSPORT; ALGORITHM; ARTICLE; BIOAVAILABILITY; CALCULATION; CHELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FILTER; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MEMBRANE PERMEABILITY; PREDICTION; STRUCTURE ACTIVITY RELATION; THEORETICAL MODEL;

EID: 0037369815     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10321     Document Type: Article

References (67)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and developing settings. Adv Drug Del Rev 23:3-25.
2. van de Waterbeemd H, Smith DA, Beaumont K, Walker DK. 2001. Property-based design: Otimization of drug absorption and pharmacokinetics. J Med Chem 44:1313-1333.
3. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherborne B, Cooper I, Platts JA. 2001. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the abraham descriptors. J Pharm Sci 90:749-784.
4. Barthe L, Woodley J, Houin G. 1999. Gastrointestinal absorption of drugs: Methods and studies. Fundam Clin Pharmacol 13:154-168.
5. Loebstein R, Lalkin A, Koren G. 1997. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328-343.
6. Lin JH, Lu AY. 1997. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-450.
7. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. 1999. MDCK (Madin-Darby Canine Kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88:28-33.
8. Mandagere AK, Thompson TN, Hwang KK. 2002. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304-311.
9. Wacher VJ, Salphati L, Benet LZ. 2001. Active secretion and enterocyclic drug metabolism barriers to drug absorption. Adv Drug Del Rev 46:89-102.
10. Stenberg P, Norinder U, Luthman K, Artursson P. 2001. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44:1927-1937.
11. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. 1998. Estimations of permeability by passive diffusion through Caco-2 cell monolayers using the drugs'lipophilicity and molecular weight. Eur J Pharm Sci 6:313-319.
12. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. 1998. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 41:4939-4949.
13. Oprea TI, Gottfries J. 1999. Toward minimalistic modeling of oral drug absorption. J Mol Graph Model 17:261-274.
14. Palm K, Stenberg P, Luthman K, Artursson P. 1997. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568-571.
15. Wessel MD, Jurs PC, Tolan JW, Muskal SM. 1998. Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci 38:726-735.
16. Gohlke H, Dullweber F, Kamm W, Behrens I, Marz J, Kissel T, Klebe G. 2001. Neural network based prediction of human intestinal absorption. New Approaches in Drug Design and Discovery, International Workshop, March 19-22, Schloss Rauischholzhausen, Germany.
17. Andrews CW, Bennett L, Yu LX. 2000. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship. Pharm Res 17:639-644.
18. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623.
19. Chen X, Rusinko A III, Young SS. 1998. Recursive partitioning analysis of a large structure-activity data set using three-dimensional descriptors. J Chem Inf Comput Sci 38:1054-1062;
20. Rusinko A III, Farmen MW, Lambert CG, Brown PL, Young SS. 1999. Analysis of a large structure/biological activity data set using recursive partitioning. J Chem Inf Comput Sci 39:1017-1026;
21. Chen X, Rusinko A III, Tropsha A, Young SS. 1999. Automated pharmacophore identification for large chemical data sets. J Chem Inf Comput Sci 39:887-896.
22. Japertas P, Didziapetris R, Petrauskas A. 2002. Fragmental methods in the design of new compounds. Applications of advanced algorithm builder. Quant Struct-Activity Relat 21:23-37.
23. Dollery C, editor. 1999. Therapeutic drugs, 2nd ed. London: Churchill Livingstone.
24. Moffat AC, Jackson JV, Moss MS, Widdop B, editors. 1986. Clarke's isolation and identification of drugs in pharmaceuticals, body fluids, and postmortem material, 2nd ed. London: The Pharmaceutical Press.
25. Hardman JG, Goodman Gillman A, Limbird LE, editors. 1996. Goodman & Gillman's The pharmacological basis of therapeutics, 9th ed. New York: McGraw Hill.
26. Physicians' desk reference (48 and 51 editions). Medical Economics Data Production Company.
27. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER), New and generic drug approval (prescription information) www.fda.gov/cder/approval/index.htm, site accessed 2002.02.01.
28. Sietsema WK. 1989. The absorption and oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27:179-211.
29. Dantzig AH, Duckworth DC, Tabas LB. 1994. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochim Biophys Acta 1191:7-13.
30. Koepsell H. 1998. Organic cation transporters in intestine kidney, liver, and brain. Annu Rev Physiol 60:243-266.
31. Nolte K, Backfisch G, Neidlein R. 2000. In vitro studies of poorly absorbed drugs using porcine intestine in the ring model RIMO. Arzneimittelforschung/Drug Res 50:664-668.
32. Yu DK. 1999. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmcol 39:1203-1211.
33. Bretschneider B, Brandsch M, Neubert R. 1999. Intestinal transport of beta-lactam antibiotics: Analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res 16: 55-61.
34. Wu X, Whitfield LR, Stewart BH. 2000. Atorvastatin transport in the Caco-2 cell model: Contributions or P-glycoprotein and the protonmonocarboxylic acid co-transporter. Pharm Res 17: 209-215.
35. Li YH, Ito K, Tsuda Y, Kohda R, Yamada H, Itoh T. 1999. Mechanism of intestinal absorption of orally active beta-lactam prodrug: Uptake and transport of carindacillin in Caco-2 cells. J Pharmacol Exp Ther 290:958-964.
36. Mason JB, Shoda R, Haskell M, Selhub J, Rosenberg IH. 1990. Carrier affinity as a mechanism for the ph-dependence of folate transport in the small intestine. Biochim Biophys Acta 1024: 331-335.
37. Said HM, Ortiz A, Kumar CK, Chatterjee N, Dudeja PK, Rubin S. 1999. Transport of thiamine in human intestine: Mechanism and regulation in intestinal epithelial cell model Caco-2. Am J Physiol 277:C645-C651.
38. Tsuji A, Takanaga H, Tamai I, Terasaki T. 1994. Transcellular transport of benzoic acid across Caco-2 cells by a ph-dependent and carrier-mediated transport mechanism. Pharm Res 11:30-37.
39. Stein J, Zores M, Schroder O. 2000. Short fatty acid (SCFA) uptake into Caco-2 cells by a ph-dependent and carrier mediated transport mechanism. Eur J Nutr 39:121-125.
40. Ogihara T, Tamai I, Takanaga H, Sai Y, Tsuji A. 1996. Stereoselective and carrier-mediated transport of monocarboxylic acids across Caco-2 cells. Pharm Res 13:1828-1832.
41. Takanaga H, Tamai I, Tsuji A. 1994. Ph-dependent and carrier-mediated transport of salicylic acid across Caco-2 cells. J Pharm Pharmacol 46:567-570.
42. Martel F, Calhau C, Azevedo I. 2000. Characterization of the transport of organic cation [3H]MPP+ in human intestinal epithelial (Caco-2) cells. Naunyn Shmiedebergs Arch Pharmacol 361:505-513.
43. Tranchant T, Besson P, Hoinard C, Delarue J, Antoine JM, Couet C, Gore J. 1997. Mechanisms and kinetics of alpha-linolenic acid uptake in Caco-2 clone TC7. Biochim Biophys Acta 1345:151-161.
44. Van Asperen J, Van Tellingen O, Beijnen JH. 1998. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 37:429-435.
45. Adson A, Raub TJ, Burton PS, Barsuhn CL, Hilgers AR, Audus KL, Ho NFH. 1994. Quantitative approaches to delineate paracellular diffusion in cultured etithelial cell monolayers. J Pharm Sci 83:1529-1536;
46. Adson A, Burton PS, Raub TJ, Barsuhn CL, Audus KL, Ho NFH. 1995. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: Uncoupling the contributions of hydrodynamic, transcellular and and paracellular barriers. J Pharm Sci 84:1197-1204.
47. +-independent transport systems in T84 and Caco-2 cells. Biochim Biophys Acta 1419:15-22.
48. AB/HIA is available from Pharma Algorithms, 591 Indian Rd, Toronto, ON, Canada, M6P 2C4; www.ap-algorithms.com.
49. Platts JA, Butina D, Abraham MH, Hersey A. 1999. Estimation of molecular linear free energy relationship descriptors using a group contribution approach. J Chem Inf Comput Sci 39:835-845.
50. Ertl P, Rohde B, Selzer P. 2000. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714-3717.
51. Hansch C, Leo A. 1979. Substituent constants for correlation analysis in chemistry and biology. New York: Wiley; Hansch C, Leo A, Hoekman D. 1995. Exploring QSAR: Hydrophobic, electronic and steric constants. Washington, DC: ACS.
52. Lennernas H. 1995. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm Res 12:1573-1582.
53. Artursson P, Ungell AL, Lofroth JE. 1993. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 10:1123-1129.
54. Collander R, Barlund H. 1932. Permeabilitatsstudien an Chara eratophylla. Acta Bot Fenn 11:72-114.
55. Seelig A. 1998. A general pattern for substrate recognition by P-Glycoprotein. Eur J Biochem 251: 252-261.
56. de Groot MJ, Ackland MJ, Horne VA, Alex AA, Jones BC. 1999. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:1515-1524.
57. Jelovsek FR, Mattison DR, Young JF. 1990. Eliciting principles of hazard identification from experts. Teratology 42:521-533.
58. There are two expert systems based on the substructure-specific rules gathered from independent human experts: (1) HAZARD from ComGenex (H-1395 Budapest 62, P.O. Box 405), and (2) DEREK from LHASA UK (University of Leeds, Leeds, LS2 9JT, UK).
59. There are many toxicity predicting programs that are based on QSAR or C-SAR studies performed by their original developers: (1) Topkat (www.accelrys.com/products/topkat/), (2) ToxSys (www.scivision.com), (3) M-CASE/ToxAlert (www. multicase.com), (4) OncoLogic (LogiChem), (v) COMPACT (Univ. of Surrey, Dr. Lewis).
60. Zhu C, Jiang L, Chen T-M, Hwang K-K. 2002. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37: 399-407.
61. Lipnick RL. 1991. Outliers: Their origin and use in the classification of molecular mechanisms of toxicity. Sci Tot Environ 109(110):131-153;
62. Lipnick RL. Narcosis: Fundamental and baseline toxicity mechanisms for nonelectrolyte organic chemicals. In: Karcher W, Devillers J, editors. 1990. Practical applications of quantitative structure-activity relationships (QSAR) in environmental chemistry and toxicology. Dordrect, The Netherlands: Kluwer Academic, pp 129-144.
63. Lipnick RL. 1999. Correlative and mechanistic QSAR models in toxicology. SAR QSAR Environ Res 10:239-248.
64. Zmuidinavicius D, Didziapetris R, Japertas P, Riauba L, Petrauskas A. 2002. AB/HIA: Rapid identification of poor leads. Presented at Drug Discovery Technology, April 14-18, Stuttgart, Germany.
65. Ghose AK, Viswanadhan VN, Wendoloski JJ. 1999. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55-68;
66. Oprea TI. 2000. Property distribution of drug-related chemical databases. J Comput Aided Mol Des 14:251-264;
67. Blake JF. 2000. Chemoinformatics-Predicting the physicochemical properties of "drug-like" molecules. Curr Opin Biotechnol 11:104-107.